Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)
Sister-chromatid exchanges per cell
12.0 ± 0.28 versus 5.9 ± 0.2Prostamax-exposed versus intact cells
Silver-positive nucleolar organizer regions
2.5 versus 0.95 per cellExposed versus intact cells
Prostamax increased sister-chromatid exchanges from 5.9 ± 0.2 to 12.0 ± 0.28 per cell and silver-positive nucleolar organizer regions from 0.95 to 2.5 per cell. These are chromatin assays, not prostate-symptom outcomes.
Study notes · methods, sources and limitations
Participants or model Cultured cells from donors aged 75–86 years.
Design Cultured cells from donors aged 75–86 years.
Important limitations
An increase in sister-chromatid exchange is a cellular observation, not inherently a clinical benefit. Donor number and long-term consequences are not supplied in the abstract.
Effects of short peptides on lymphocyte chromatin in senile subjects
Study of multiple preparations
Chromatin readouts
Ribosomal-gene activation and decondensation reported; no numerical treatment effect supplied
Five short peptides increased ribosomal-gene activity and altered condensed chromatin in sampled leukocytes. Epitalon, Livagen and Prostamax changed chromosome-1 pericentromeric chromatin; Epitalon and Livagen also changed chromosome 9.
Study notes · methods, sources and limitations
Participants or model Leukocytes sampled from people aged 75–88 years and exposed to peptides in culture.
Design Leukocytes sampled from people aged 75–88 years and exposed to peptides in culture.
Donor ages
75–88 years
Important limitations
People donated cells; they were not treated in a clinical trial. Chromatin changes do not establish rejuvenation or longer life. Related chromatin-program publications may overlap.
Bulletin of experimental biology and medicine 2004 · Journal publication
The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats
Study of multiple preparations
Reports tissue-specific growth responses to the corresponding synthetic peptides in organotypic cultures.
Study notes · methods, sources and limitations
Participants or model Heart, lung, prostate and pancreatic explants from young and old rats
Important limitations
Ex vivo animal tissue, not a human clinical study or evidence that an extract and peptide are interchangeable. Full methods, adverse-event reporting and independent replication remain to be appraised.
A synthetic four-amino-acid peptide, KEDP, associated with prostate-peptide research. Its linked original studies examine chromatin in cultured cells; it is distinct from the tissue extract Prostatilen.
KEDP tetrapeptide investigated in cultured-cell chromatin assays. It increased sister-chromatid exchanges and nucleolar organizer-region activity; prostate symptoms were not measured.
Compound class
Short peptide research
Research collection
Peptide bioregulation · editorial grouping
Research institutions
No institutional affiliation recorded
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH
Understanding the evidence
Human research
Cultured cells from older donors; no human intervention established
Study methods
Original indexed laboratory abstracts; not Prostatilen clinical trials
Independent replication
Independent replication not established by this collection
Source access
Primary-publication records linked; full-text versus abstract review shown per source
Safety evidence
Incomplete assessment; findings do not establish safety for personal use
Open a topic for the evidence assessment.
More findings, background and history
What remains unclear
The available experimental studies leave human benefit and safety uncertain.
No human intervention report has been identified among the linked records; unclassified archival leads may remain. Several publications can describe the same participants.
Evidence belongs to the preparation actually studied. A tissue extract and a synthetic peptide can belong to the same research tradition without having equivalent effects or safety.
Tissue-level research association only in this collection; direct molecular derivation of Prostamax from the clinical Prostatilen formulation has not been established.
Clinical evidence and limitations
Historical Prostatilen reports, a 127-patient Prostateks postoperative comparison and a separate 94-patient Prostateks prostatitis comparison are linked with distinct preparation identities.
The cited cohorts received Prostatilen. The uncontrolled results leave the treatment effect uncertain.
PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026
Patents and claimed inventions
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
2002 · RU2177802C1 · Prostamax: KEDP molecular and prostate-use claimsMolecule · Reported cessation of frequent urination in 87.5% and difficult urination in 80.7%
The patent reports urinary-symptom improvement, but the displayed clinical percentages have incompletely specified denominators.
Prostatitis symptoms
Reported cessation of frequent urination in 87.5% and difficult urination in 80.7%Narrative percentages; no verified responder counts inferred
Adenoma comparison
Subjective and urodynamic improvement reported; increased libido stated in 37.3%19 treated patients; 37.3% does not map cleanly to an integer count in this group
2002 · Prostamax: KEDP molecular and prostate-use claims — RU2177802C1Prostatitis symptoms: Reported cessation of frequent urination in 87.5% and difficult urination in 80.7%
2002Patent / reported experimentsFull text available
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
The patent reports urinary-symptom improvement, but the displayed clinical percentages have incompletely specified denominators.
Prostamax/KEDP patent includes prostatitis observations and a prostate-adenoma comparison of 19 treated versus 17 conventional-care patients.
Results · Clinical Examples 6–7 and narrative around Tables 3–4.
Measure
Result
Comparison, timing and statistics
Prostatitis symptoms
Reported cessation of frequent urination in 87.5% and difficult urination in 80.7%
Narrative percentages; no verified responder counts inferred
Adenoma comparison
Subjective and urodynamic improvement reported; increased libido stated in 37.3%
19 treated patients; 37.3% does not map cleanly to an integer count in this group
Small incompletely reported comparisons, variable exposures and unclear percentage denominators prevent a reliable treatment effect. The molecular sequence is distinct from Prostatilen extract.
Prostamax/KEDP patent includes prostatitis observations and a prostate-adenoma comparison of 19 treated versus 17 conventional-care patients.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
This peptide is not a generic prostate extract or an unrelated supplement sold under a similar name.
Small incompletely reported comparisons, variable exposures and unclear percentage denominators prevent a reliable treatment effect. The molecular sequence is distinct from Prostatilen extract.
Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Read the source ↗2004 · Effects of short peptides on lymphocyte chromatin in senile subjectsChromatin readouts: Ribosomal-gene activation and decondensation reported; no numerical treatment effect supplied
Khavinson VKh, Lezhava TA, Malinin VV · Bulletin of experimental biology and medicine 2004
Five short peptides increased ribosomal-gene activity and altered condensed chromatin in sampled leukocytes. Epitalon, Livagen and Prostamax changed chromosome-1 pericentromeric chromatin; Epitalon and Livagen also changed chromosome 9.
Results and tables
Reported findings and study design
Five short peptides increased ribosomal-gene activity and altered condensed chromatin in sampled leukocytes. Epitalon, Livagen and Prostamax changed chromosome-1 pericentromeric chromatin; Epitalon and Livagen also changed chromosome 9.
Leukocytes sampled from people aged 75–88 years and exposed to peptides in culture.
Results · Primary-publication indexed abstract
Measure
Result
Comparison, timing and statistics
Chromatin readouts
Ribosomal-gene activation and decondensation reported; no numerical treatment effect supplied
Donor ages
75–88 years
People donated cells; they were not treated in a clinical trial. Chromatin changes do not establish rejuvenation or longer life. Related chromatin-program publications may overlap.
Leukocytes sampled from people aged 75–88 years and exposed to peptides in culture.
Source reviewed
Original-publication metadata and indexed abstract checked in Europe PMC. No unavailable full-text figures inferred.
Study limitations
People donated cells; they were not treated in a clinical trial. Chromatin changes do not establish rejuvenation or longer life. Related chromatin-program publications may overlap.
Reviewed 2026-11-01.
Read the source ↗2012 · Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)Sister-chromatid exchanges per cell: 12.0 ± 0.28 versus 5.9 ± 0.2
Dzhokhadze TA, Buadze TZh, Gaĭozishvili MN, Baratashvili NA, Lezhava TA · Georgian medical news 2012
Prostamax increased sister-chromatid exchanges from 5.9 ± 0.2 to 12.0 ± 0.28 per cell and silver-positive nucleolar organizer regions from 0.95 to 2.5 per cell. These are chromatin assays, not prostate-symptom outcomes.
Results and tables
Reported findings and study design
Prostamax increased sister-chromatid exchanges from 5.9 ± 0.2 to 12.0 ± 0.28 per cell and silver-positive nucleolar organizer regions from 0.95 to 2.5 per cell. These are chromatin assays, not prostate-symptom outcomes.
Cultured cells from donors aged 75–86 years.
Results · Primary-publication indexed abstract
Measure
Result
Comparison, timing and statistics
Sister-chromatid exchanges per cell
12.0 ± 0.28 versus 5.9 ± 0.2
Prostamax-exposed versus intact cells
Silver-positive nucleolar organizer regions
2.5 versus 0.95 per cell
Exposed versus intact cells
An increase in sister-chromatid exchange is a cellular observation, not inherently a clinical benefit. Donor number and long-term consequences are not supplied in the abstract.
Original-publication metadata and indexed abstract checked in Europe PMC. No unavailable full-text figures inferred.
Study limitations
An increase in sister-chromatid exchange is a cellular observation, not inherently a clinical benefit. Donor number and long-term consequences are not supplied in the abstract.
Reviewed 2026-11-01.
Read the source ↗2006 · The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats
V. Kh. Khavinson, A. Yu. Solovyev, S. I. Tarnovskaya, N. S. Linkova · Biology Bulletin Reviews 3(6):451–455
Mechanistic review with a table of 15 short peptides on page 453. Tissue labels in the research map are the authors’ proposed targets, not established clinical indications.
Population / setting
Review of earlier research
Source reviewed
Author-hosted English PDF and its peptide table checked. Each cited experiment remains a separate appraisal task.
Study limitations
Source-linked does not mean a completed risk-of-bias review.
A review is not an independent clinical replication; proposed mechanisms do not establish efficacy or safety.